<?xml version="1.0" encoding="UTF-8"?>
<urlset
  xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
  xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://glpwatchdog.org/research/alcohol-and-glp1s</loc>
    <news:news>
      <news:publication>
        <news:name>GLP Watchdog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T00:00:00.000Z</news:publication_date>
      <news:title>Drinking on a GLP-1: What the Label Actually Says</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://glpwatchdog.org/research/foundayo-orforglipron-oral-glp1</loc>
    <news:news>
      <news:publication>
        <news:name>GLP Watchdog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T00:00:00.000Z</news:publication_date>
      <news:title>Foundayo (Orforglipron): the First GLP-1 Pill for Weight</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals</loc>
    <news:news>
      <news:publication>
        <news:name>GLP Watchdog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T00:00:00.000Z</news:publication_date>
      <news:title>GLP-1 Prior Authorization: the Criteria, the Clock, the Appeal</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://glpwatchdog.org/research/medicare-glp1-bridge</loc>
    <news:news>
      <news:publication>
        <news:name>GLP Watchdog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T00:00:00.000Z</news:publication_date>
      <news:title>Medicare and GLP-1s: the $50 Bridge That Opened in July</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://glpwatchdog.org/research/cjc-1295-ipamorelin-stack</loc>
    <news:news>
      <news:publication>
        <news:name>GLP Watchdog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T00:00:00.000Z</news:publication_date>
      <news:title>CJC-1295 and Ipamorelin: What FDA Recorded</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://glpwatchdog.org/research/sermorelin-for-weight-loss</loc>
    <news:news>
      <news:publication>
        <news:name>GLP Watchdog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T00:00:00.000Z</news:publication_date>
      <news:title>Sermorelin for Weight Loss: Zero Trials, Real History</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://glpwatchdog.org/research/brand-names-vs-molecules</loc>
    <news:news>
      <news:publication>
        <news:name>GLP Watchdog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T00:00:00.000Z</news:publication_date>
      <news:title>Is Zepbound a Semaglutide? Brand Names vs Molecules</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://glpwatchdog.org/research/tesamorelin-for-weight-loss</loc>
    <news:news>
      <news:publication>
        <news:name>GLP Watchdog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-16T00:00:00.000Z</news:publication_date>
      <news:title>Tesamorelin for Weight Loss? Read Its Own Label</news:title>
    </news:news>
  </url>
</urlset>